STF Management’s Vertex Pharmaceuticals VRTX Stock Holding History

STF Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$677K	Sell	1,494 -2,492	-63%	-$1.07M	0.64%	37
2025 Q3	$1.56M	Sell	3,986 -109	-3%	-$45.6K	0.58%	38
2025 Q2	$1.82M	Buy	4,095 +96	+2%	+$44.2K	0.72%	35
2025 Q1	$1.94M	Sell	3,999 -22	-0.5%	-$10.3K	0.93%	27
2024 Q4	$1.62M	Buy	4,021 +320	+9%	+$148K	0.73%	31
2024 Q3	$1.72M	Sell	3,701 -420	-10%	-$202K	0.78%	27
2024 Q2	$1.93M	Sell	4,121 -201	-5%	-$87.2K	0.81%	30
2024 Q1	$1.81M	Buy	4,322 +52	+1%	+$22K	0.78%	30
2023 Q4	$1.74M	Buy	4,270 +43	+1%	+$15.9K	0.82%	29
2023 Q3	$1.47M	Buy	4,227 +2,562	+154%	+$896K	0.78%	31
2023 Q2	$586K	Sell	1,665 -1,286	-44%	-$433K	0.63%	31
2023 Q1	$930K	Buy	2,951 +1,238	+72%	+$371K	0.63%	34
2022 Q4	$495K	Buy	+1,713	New	+$522K	0.71%	34

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

STF Management's VRTX Position: Q4 2025 in Review

STF Management reduced its Vertex Pharmaceuticals (VRTX) stake by 63% in Q4 2025, selling an estimated $1.07M and leaving 1,494 shares worth $677K. The position accounts for 0.64% of the portfolio, ranked #37.

STF Management first reported a position in VRTX in Q4 2022 and has held it in 13 quarters since. The position peaked at $1.94M in Q1 2025. 1,668 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

STF Management held 1,494 shares of Vertex Pharmaceuticals worth $677K as of Q4 2025.
STF Management sold 2,492 Vertex Pharmaceuticals shares in Q4 2025, an estimated $1.07M.
Vertex Pharmaceuticals made up 0.64% of STF Management's portfolio in Q4 2025, its #37 holding.
STF Management first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 13 quarters since.
STF Management's Vertex Pharmaceuticals position peaked at $1.94M in Q1 2025.
1,668 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on STF Management's 13F filing for Q4 2025, filed 5 Feb 2026.